GlucoTrack, Inc.

GlucoTrack, Inc. is a medical device company dedicated to reimagining continuous glucose monitoring through innovative research and thoughtful design. Headquartered in Rutherford, New Jersey, the company's mission is to develop less disruptive and more intuitive solutions for individuals living with diabetes. While its roots in glucose monitoring technology research date back to 2000, the company formally established as GlucoTrack, Inc. in November 2021, having previously operated as Integrity Applications, Inc..

The company's primary focus is the development of a long-term implantable continuous blood glucose monitor (CBGM). This investigational device is designed to measure glucose directly from the blood for up to three years, eliminating the need for on-body wearable components and requiring minimal calibration. GlucoTrack aims to serve the market segments of Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients with this technology.

Led by President and CEO Paul V. Goode, PhD, GlucoTrack is currently a clinical-stage, pre-revenue company focused on advancing its investigational device through clinical trials and regulatory processes. In March 2025, the company presented positive first-in-human study results for its CBGM at the International Conference on Advanced Technologies & Treatment for Diabetes (ATTD), demonstrating safety, feasibility, and promising performance with a Mean Absolute Relative Difference (MARD) of 7.7%. However, the company has also received a NASDAQ delisting notice related to listing rule deficiencies.